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Abstract 
Background: Rare disease patient‑reported outcome measures (PROMs) require linguistic adaptation to overcome 
the challenge of geographically dispersed patient populations. Importantly, PROMs such as health‑related quality 
of life (HRQoL) should accurately capture responses to patient‑identified concerns. The Systemic Sclerosis Quality of 
Life Questionnaire (SScQoL) is a 29‑item tool validated in six languages. Previous evaluation of the German version 
revealed problems with dichotomous responses. This study aimed to revise the German SScQoL, extend the response 
structure, and evaluate content and construct validity, reliability and unidimensionality.
Methods: The instrument validation study involved revising the German SScQoL response structure, cognitive 
debriefing with patients and validation using Rasch analysis. The revised SScQoL was completed by Swiss‑German‑
speaking patients with SSc within the Swiss MANagement Of Systemic Sclerosis (MANOSS) study. Rasch analysis was 
employed to test the validity, reliability and unidimensionality of the revised instrument.
Results: Based on cognitive debriefing with patients (n = 6) dichotomous items were extended to a polytomous 
4‑point response structure. A total of 78 patients completed the revised SScQoL. Initial analysis of the 29 items sug‑
gested the scale lacked fit to the model (χ2 = 51.224, df = 29, p = 0.007). Grouping items into five domains resulted 
in an adequate fit to the Rasch model (χ2 = 5.343, df = 5, p = 0.376) and unidimensionality (proportion of significant 
independent t tests: 0.045, 95% CI 0.016–0.114). Overall, the scale was well targeted, had high internal consistency 
(Person Separation Index, PSI = 0.931) and worked consistently in patients with different demographic and clinical 
characteristics.
Conclusions: The revised German SScQoL has a 4‑point response structure and is a valid, reliable measure. Rasch 
analysis is useful for validating continuous response structure of quality of life measures. Further evaluation of 
measurement equivalence with other German‑speaking cultures is required for multinational comparisons and data 
pooling.
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Background
For many rare diseases, the natural history of the con-
dition is poorly understood especially as it relates to 
the impact on health-related quality of life (HRQoL). 
Importantly, patients affected by rare diseases are geo-
graphically dispersed. Therefore, validated patient-
reported outcome measures (PROMs) including 
HRQoL are needed in multiple languages. Systemic 
sclerosis (SSc) is a rare multisystemic, connective tis-
sue disease associated with significant morbidity, 
physical and psychosocial impact [1]. Pathogenesis is 
dominated by vascular problems such as vasospasm of 
digital arteries (Raynaud’s phenomenon); inflammation 
and activation of (auto)immune response; and fibro-
sis of the skin and visceral organs causing irreversible 
scarring and organ failure. The disease is heterogene-
ous in clinical manifestations (e.g. autoantibody profile, 
disease progression, skin involvement) and patients 
are typically grouped into two disease subsets: limited 
cutaneous systemic sclerosis (lcSSc) and diffuse cutane-
ous systemic sclerosis (dcSSc).
Importantly, SSc is a long-term condition and both 
disease subsets exhibit multiple symptoms includ-
ing fatigue, hand stiffness, digital ulcers, shortness of 
breath, pain, and mouth-, dental- and gastrointestinal-
problems [2, 3]. Psychosocial problems such as work 
disability, depression, fear of disease progression, and 
body image dissatisfaction are often evident [4, 5]. 
Accordingly, patients’ quality of life is often severely 
affected [6, 7]. Notably, the diffuse form (dcSSc) is asso-
ciated with greater negative impact on quality of life 
compared to limited SSc (lcSSc) without organ damage 
[6].
To systematically address the range of SSc effects, it is 
important to assess disease-specific aspects of HRQoL 
using an outcome measure with demonstrated reli-
ability and validity for some specific languages. HRQoL 
measures are fundamental in developing PROMs for 
chronic conditions to evaluate targeted interven-
tions, increase well-being (e.g., detect need for sup-
portive care), and reduce costs (e.g., earlier detection 
of relapses) [8–10]. Indeed, to achieve adequate sam-
ple sizes, rare disease research relies on registries (e.g. 
EUSTAR and EUSHNet) and demands international/
multicenter collaboration given the limited number of 
affected individuals [11].
While the Health Assessment Questionnaire (HAQ) 
is a valid measure of physical disability, and commonly 
used for evaluating patients, it does not adequately take 
into account the psychosocial aspects or other disease-
specific impact in people with SSc [12]. The Systemic 
Sclerosis Quality of Life Questionnaire (SScQoL) is the 
first PROM assessing disease-specific HRQoL in people 
with SSc [13, 14]. Reay et al. developed the instrument 
through a multi-phased process comprising qualitative 
interviews (one-to-one interview and focus groups) 
with people with SSc; development of the descriptive 
framework of SSc QoL; development of draft items 
derived from patients statements (90 items); Rasch 
analysis and item reduction (researchers with patient 
input—29 items); test–retest with hypothesis testing 
and structural equation modelling [14]. The devel-
oped SScQoL has 29 items with dichotomous (true/not 
true) responses, scored as ‘True’ = 1 or ‘Not true’ = 0, 
total score ranges between 0 and 29 with higher scores 
indicating a greater impact of the disease and conse-
quently, decreased HRQoL [13, 14]. The items have 
been grouped into five domains which map onto the 
International Classification of Functioning, Disability 
and Health (ICF) framework [13], with scores for each 
domain ranging as follows: function: 0–6; emotional: 
0–13; sleep: 0–2; social: 0–6; and pain: 0–2.
The SScQoL underwent a cross-cultural adaptation 
according to a five-step procedure described by Beaton 
et al. and validation in six European countries [13, 15]. As 
part of the cross-cultural adaptation the translated ver-
sions of the SScQoL were first completed by a group of 
30 patients in each of the six countries (Germany, France, 
Italy, Poland, Spain, Sweden, and UK) who commented 
on the translated version before different versions were 
sent for psychometric testing using Rasch analysis [13]. 
Findings of the adaptation suggested a seamless adapta-
tion across all countries but Germany where patients 
documented problems with 10 items [13]. Specifically, 
problems were identified in relation to the dichotomous 
‘true/not true’ response structure in those items. Ger-
man patients indicated a desire for a broader response 
structure to more accurately capture the full range of 
responses. In the subsequent psychometric testing phase, 
those items in the German SScQoL revealed significant 
deviations from the Rasch model, confirming the prob-
lems highlighted by patients. This suggested the need 
for revision of the German SScQoL [13]. The need for 
revision was in the item wording/presentation, response 
structure and further psychometric testing of the Ger-
man SScQoL. The aim of this present study was to review 
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the German SScQoL, expand the response structure, and 
examine content validity, construct validity, unidimen-
sionality, and reliability of the scale.
Methods
Design
This study consisted of two phases involving cognitive 
interviews for clarifying the cultural adaptation and a 
validation study to establish measurement validity of 
the adapted tool. In Phase 1, the SScQoL was refined in 
accordance with the International Society for Pharma-
coeconomics and Outcomes Research (ISPOR) guideline 
[16, 17]. Phase 2, drew on data from the MANagement 
Of Systemic Sclerosis (MANOSS) cross-sectional study 
carried out in Switzerland [18, 19]. The MANOSS pro-
ject aims to fill existing gaps in SSc care by developing 
an eHealth-enhanced rare disease chronic care model 
for SSc patients in Switzerland. Part of the MANOSS 
project involves conducting baseline data of SSc patients 
before implementing a new model of care (i.e., HRQoL). 
The MANOSS study was reviewed and approved by the 
responsible Swiss ethics committee in September 2018 
(EKNZ 2018‐01206).
Measures
In phase 1, the original English SScQoL and Ger-
man translation were compared independently by two 
researchers from Germany (KH) and Switzerland (AK) 
respectively. The revised translations of both research-
ers were discussed until consensus was achieved. Sub-
sequently, an expert committee (MN, DN, KH, AK) 
expanded the response structure for items 1, 3–5, 7–14, 
16–17, 19–22, and 25–29 from dichotomous (true/not 
true) into polytomous (‘always’, ‘usually’, ‘sometimes’, 
‘never’) responses. The final version was back-translated 
into English language by a professional translator. In cog-
nitive interviews, a convenience sample of patients with 
SSc completed the new version while ‘thinking aloud’ and 
commented on relevance of the items and the response 
structure. Briefly, participants were encouraged to read 
all SScQoL items while verbalizing their thoughts con-
currently. Additionally, cognitive interviews were used 
for cognitive debriefing to identify problems interpret-
ing items and response options in the intended way [20, 
21]. This approach has shown to be appropriate for qual-
ity of life items and for detecting unanticipated problems 
in participant response behaviour with minimal inter-
viewer-imposed bias [20, 22].
In phase 2, the validation study, German-speaking SSc 
patients of the MANOSS cross-sectional survey (March–
August 2019) completed the revised (polytomous) SSc-
QoL [18]. Participants completed either a paper format 
version and returned it by mail or completed the revised 
SScQoL in a web-based format. Participants provided 
sociodemographic data (sex, age, education, employ-
ment status), self-reported disease information (subset: 
lSSc, dSSc, Overlap  syndrome1 or unknown), and disease 
duration.
Participants
For phase 1, a convenience sample of six SSc patients 
spanning a range of SSc disease severity/experiences 
and with varied educational levels was recruited from a 
Swiss University hospital (Inselspital, Bern, Switzerland), 
a German University hospital (Medizinische Hochs-
chule Hannover, Germany) and a German outpatient 
rheumatology clinic (rheumapraxis an der hase, Osna-
brück, Germany). They were included if they (1) had 
an SSc diagnosis assured by a physician, were (2) adult 
(> 18  years), and (3) understood the German language. 
They were asked to assess the face validity of the revised 
SScQoL. For phase 2, patients were recruited according 
to the MANOSS protocol [18]. Patients were recruited 
from four Swiss University hospitals, one regional (can-
tonal) hospital, rheumatology outpatient clinics, and the 
Swiss SSc patient association. Participants were included 
if they were (1) adult (> 18 years), (2) received care in the 
Swiss healthcare system, and (3) understood the German 
language.
Data analysis
Cognitive interview data were analysed by an expert 
committee (AK, MN, KH, AR, DN) who made final deci-
sions on the revised German SScQoL. For phase 2, the 
Swiss sample is described using descriptive statistics 
including frequencies, percentages, median, interquartile 
range (IQR), mean and standard deviation (SD). To assess 
whether the German SScQoL had retained its validity 
and reliability following the revision process, we used 
Rasch analysis—a psychometric testing technique that 
compares collected data with the Rasch model [19, 23]. 
Originally used in education, Rasch analysis has gained 
wide acceptance in the health sciences [19]. Fit to the 
Rasch model implies construct validity, reliability and 
statistical sufficiency of the item scores [23]. Rasch analy-
sis was performed using RUMM2030 software (Perth, 
WA: RUMM Laboratory Pty Ltd) with the Master’s Par-
tial Credit Model (PCM), a polytomous generalization 
of the Rasch model, which does not impose a common 
threshold structure across all items [19].
First, each of the 29 SScQoL items was assessed for 
‘fit’ to the Rasch model to examine how the 29-item tool 
works as a scale. Second, items were grouped into the 
5-domains established in the previous cross-cultural 
validation study (Ndosi et al.) and tested as a 5-subscale 
measure of quality of life in SSc. Detailed descriptions of 
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the Rasch model requirements are published elsewhere 
[19]. Briefly, model fit was tested by Chi-square-based 
fit statistics comparing differences between observed 
values and those expected by the model, i.e., (i) item-
person interaction statistics, expressed as a Z score are 
expected to have a mean of zero (range − 2.5 to 2.5) and 
standard deviation (SD) of one and (ii) a non-significant 
Chi-square probability. In addition to fit statistics, inter-
nal consistency (inter-relatedness of items) demonstrat-
ing scale reliability was assessed using Person Separation 
Index (PSI) which functions in the same way as Cron-
bach’s alpha but is expressed in a logit scale. A minimal 
PSI value of 0.7 is accepted for assessment at a group level 
and 0.85 for individual level [19]. Another type of reliabil-
ity, the invariance of the tool (also known as differential 
item functioning—DIF) was established by testing if there 
was a response bias by different subgroups of patients 
based on personal and clinical characteristics (sex, age, 
educational background and type of SSc). DIF is tested 
by assessing item-trait Chi-square interaction statistic 
and a non-significant Bonferroni-adjusted probability to 
determine if the tool performs consistently across differ-
ent subgroups of patients. Principal component analysis 
and t test-based method was used to assess (strict) uni-
dimensionality of the scale as previously described [24]. 
This test compares two sets of items hypothesized to rep-
resent low levels and high levels of the construct (quality 
of life), selected based on the correlation between items 
and the first residual factor. The difference in estimates 
for each person are compared using an independent 
t-test. Unidimensionality is confirmed if  ≤ 5% of t tests 
are significant or if the lower bound of a binomial 95% 
CI of the observed proportion overlap 5% [24]. A p value 
of < 0.05 was considered significant—except when a Bon-
ferroni adjustment was applied to account for multiple 
testing (i.e. 0.05/number of tests). IBM® SPSS® Version 
26. Armonk, NY: IBM Corp. and RUMM2030 software, 




A convenience sample of German-speaking patients with 
SSc from Germany (n = 4) and Switzerland (n = 2) com-
pleted the new SScQoL version using “thinking aloud” 
techniques for cognitive interviews (Additional File 1). 
Patients identified some problems with item wording and 
the remaining dichotomous (true/not true) responses. 
Specifically, participants desired greater differentiation 
beyond a binary choice (i.e. addition of ‘sometimes’). 
Based on patient feedback, the expert committee (AK, 
MN, KH, AR, DN) decided to expand the 4-point 
response structure to all items. A summary of issues 
raised for each item during back-translation and cogni-
tive interviews is presented in Additional File 1.
Cross‑sectional validation study
Patient characteristics
The validation study sample comprised 78 Swiss-Ger-
man patients with SSc. They had a median self-reported 
disease duration (i.e. date of diagnosis) of 8  years (IQR 
4–13 years) and the majority, 58/78 (74.7%) were women. 
Participants’ sociodemographic data are summarized in 
Table 1. The descriptive results including frequency and 
distribution of all items are shown in Additional File 2.
Response scale structure
After expanding the response structure, item character-
istic curves (ICC) revealed that 22/29 displayed ordered 
thresholds suggesting that the response categories repre-
sented by the thresholds were ordered from low to high 
(quality of life) as expected (Additional File 3). Collaps-
ing some categories and rescoring items with disordered 
thresholds improved the individual item fit but not the 
overall scale.
Fit to the model
Item fit statistics for individual items are shown in 
Table 2a. Most individual items, appeared to adequately 
fit the model limits (residuals within the − 2.5 to 2.5 
range) with non-significant Chi-Square Bonferroni-
adjusted probability (p = 0.0017). The sole exception 
was item 29 with a fit residual of − 2.573. This may have 
impacted on the overall validity of the scale (summary 
statistics indicating deviation from the model) as shown 
in Table  3 (Chi-Square = 52.198, DF = 29, p = 0.005). 
When the items were grouped in their respective 
domains and analysed (Table 2b), each domain was found 
to adequately fit the model. Summary statics indicate the 
5-domain structure has adequate fit to the model (Chi-
Square = 5.269, df = 5, p = 0.384) (Table 3). The reliability 
of the scale was high (PSI = 0.915). The proportion of sig-
nificant t-tests was < 5% (i.e. 0.0649, 95% CI 0.016–0.114) 
supporting the unidimensionality of the scale.
Targeting of persons and items
The revised 29-item German SScQoL version integrat-
ing a 4-point response option for all items was shown 
to cover the full range of participants’ quality of life. The 
person–item threshold distribution (Fig.  1) depicts that 
the items are well mapped against all persons.
Invariance of the SScQoL
The test of invariance found that there were no signifi-
cant DIF by any personal characteristics (age, sex, edu-
cation level) or disease subcategory and disease duration. 
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The results of DIF analysis are presented in Additional 
Files 4 and 5.
Testing the fit of the dichotomized scale
As the response structure of the scale has been expanded 
to 4 responses, comparison of measures with other coun-
tries would require a cross-cultural measurement equiva-
lence which may first require dichotomizing responses of 
the revised scale. For all items, collapsing categories 1, 2 
and 3 vs category 4 provided the best model fit in indi-
vidual items (domains) and the summary statistics (Addi-
tional File 6).
Discussion
In the present study, we revised the German SScQoL 
with the aim to linguistically review the German SSc-
QoL, expand the response structure, and used Rasch 
analysis to examine construct validity, unidimensionality, 
and reliability. Overall, the scale was well targeted, had 
high internal consistency, and worked consistently across 
patients with varied demographic and clinical charac-
teristics. The present data suggest the revised German 
SScQoL can now be used with confidence in German-
speaking countries.
Cognitive interviews included patients from Germany 
and Switzerland to gain an understanding of how well 
patients comprehend the concepts intended by the items 
and how the new response structure worked for them. 
Cognitive interviews and subsequent expert discussions 
revealed translation and language issues that are essen-
tial for using the SScQoL in all four German-speaking 
countries (Austria, Germany, Liechtenstein, Switzerland). 
We made minor linguistic changes enabling use across 
German-speaking countries. The initial validation study 
[13] identified ten items that patients found too restric-
tive and also lacked fit to the Rasch model. In the pre-
sent study, cognitive interviews informed modification 
of the response structure thereby facilitating more accu-
rate responses. Polytomous responses (‘always’, ‘usually’, 
‘sometimes’, ‘never’) were applied to all items—although 
linguistically, this may not always make sense (e.g. for 
item Q23: ‘I have had to stop some of my hobbies’). Impor-
tantly, there is no definitive consensus on the most 
appropriate translation or questionnaire response for-
mat for measuring HRQoL [15]. In the present study, 
expanding all items to a uniform, 4-point response struc-
ture improved the validity and reliability of the German 
SScQoL. Although there is not necessarily semantic or 
linguistic equivalence with the English SScQoL, expert 
meetings and cognitive interviews support conceptual 
equivalence between the English and German versions.
Rasch analysis confirmed that measurement properties 
(construct validity, reliability, and unidimensionality) of 
Table 1 Validation study: Participant characteristics (n = 78)
1 Overlap syndrome: Condition in which patients have concurrent clinical 
manifestations of multiple distinct immune diseases (e.g. overlap between 
systemic sclerosis and rheumatoid arthritis) 2Multiple answers were allowed
Characteristic n (%)
Instrument format
Online survey 25 (32.1%)




Not reported 2 (2.6%)
Age [years, median (IQR)] 61 (49–71)
Disease duration, self‑reported [years, median (IQR)] 8 (4–13)
Not reported 5
Disease subset, self‑reported
Limited cutaneous systemic sclerosis (lSSc) 28 (35.9%)
Diffuse cutaneous systemic sclerosis (dSSc) 22 (28.2%)
Overlap  syndrome1 3 (3.9%)
Don’t’ know 20 (25.6%)
Not reported 5 (6.4%)
Comorbidities, self‑reported
Gastrointestinal problems 46 (58.2%)
Osteoarthritis 32 (40.5%)
Backpain 31 (39.2%)
Lung problems 28 (35.4%)
High blood pressure 24 (30.4%)
Heart problems 22 (27.8%)
Depression 12 (15.2%)
Anemia or other blood problems 10 (12.7%)
Liver problems 9 (11.4%)
Diabetes 5 (6.3%)




Divorced, separated, or widowed 13 (16.7%)
Not reported 2 (2.5%)
Education
Tertiary level (e.g. university of applied science) 32 (41.1%)
Upper secondary (e.g. Baccalaureate schools) 34 (43.5%)
Compulsory (e.g. high school) 10 (12.8%)
No completed school education or vocational training 1 (1.3%)
Not reported 1 (1.3%)
Employment2
Employed 38 (48.7%)
 Working full time (80–100% employed) 17/38 (21.8%)
 Working part time (less than 80% employed) 21/38 (26.9%)
Looking for work 4 (5.1%)
In training (student, vocational education) 7 (9.0%)
Retired 19 (24.4%)
On disability or sick leave 10 (12.8%)
Not reported 1 (1.3%)
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Table 2 Fit statistics for individual items and subscales
DF, degree of freedom; SE, standard error; p value*, Bonferroni adjusted p-value = 0.05/number of tests (items), Numbers in bold suggest deviation from the model
Item Location SE Fit residual DF Chi‑Square DF p value*
a: Individual item fit statistic
Item 1 − 0.0690 0.1980 0.7720 71.30 0.7350 1 0.3913
Item 2 0.8040 0.2000 − 0.1080 71.30 0.0950 1 0.7575
Item 3 − 0.5990 0.2040 0.7390 69.45 0.4630 1 0.4961
Item 4 − 0.5850 0.2080 1.4080 70.37 1.7500 1 0.1859
Item 5 0.5520 0.1870 2.0380 71.30 6.9000 1 0.0086
Item 6 − 0.7860 0.2240 0.4820 69.45 0.0430 1 0.8361
Item 7 0.5300 0.1650 − 0.0030 70.37 0.0590 1 0.8088
Item 8 0.3000 0.1700 − 1.5930 70.37 0.7270 1 0.3940
Item 9 0.1440 0.1760 1.4490 70.37 0.5550 1 0.4562
Item 10 0.1980 0.1720 − 1.0090 70.37 0.8430 1 0.3586
Item 11 − 0.0240 0.1880 − 0.0300 71.30 1.1780 1 0.2777
Item 12 1.9560 0.1660 2.0370 71.30 1.6340 1 0.2011
Item 13 0.0080 0.1910 − 1.3440 69.45 1.2680 1 0.2602
Item 14 1.3880 0.1640 − 0.1000 70.37 0.0840 1 0.7720
Item 15 0.5680 0.1770 − 0.5930 69.45 1.2140 1 0.2705
Item 16 − 0.1550 0.1860 − 0.1190 68.52 0.0040 1 0.9525
Item 17 − 0.1520 0.1970 − 0.1290 69.45 0.5860 1 0.4438
Item 18 1.2400 0.1670 0.5370 70.37 0.0130 1 0.9100
Item 19 − 1.6870 0.2340 − 1.2330 70.37 4.8620 1 0.0274
Item 20 − 0.0900 0.1790 0.6500 70.37 1.6790 1 0.1950
Item 21 − 2.0530 0.2340 − 1.4820 69.45 7.6950 1 0.0055
Item 22 0.8940 0.1670 − 0.1830 70.37 0.0140 1 0.9060
Item 23 1.0750 0.1620 1.6730 70.37 5.2190 1 0.0223
Item 24 − 1.8890 0.2630 − 0.2340 69.45 0.0220 1 0.8822
Item 25 − 0.6260 0.1870 0.4180 70.37 0.2140 1 0.6437
Item 26 0.3040 0.1910 − 1.2790 70.37 2.9170 1 0.0876
Item 27 − 0.6810 0.2030 − 1.3730 71.30 4.9500 1 0.0261
Item 28 − 0.5330 0.2000 − 1.2820 70.37 1.2640 1 0.2609
Item 29 − 0.0350 0.1690 − 2.5730 71.30 4.2360 1 0.0396
b: Fit statistics for each domain (subscale)
Function 0.618 0.129 0.215 51.65 1.339 1 0.2473
Emotional − 0.075 0.079 − 1.05 49.4 0.202 1 0.6528
Sleep − 0.294 0.172 0.236 53.15 0.038 1 0.8445
Social − 0.16 0.109 − 0.22 50.15 1.933 1 0.1644
Pain − 0.089 0.19 − 0.13 51.65 1.757 1 0.1850
Table 3 Summary fit statistics
SD, Standard deviation; df, degrees of freedom; PSI, Person separation index
Analysis Item Fit Residual Person Fit Residual Chi Square Interaction Unidimensionality
Mean SD Mean SD Value (df) p PSI N Independent t‑tests (95% CI)
Individual items − 0.0849 1.1739 − 0.19 1.313 51.2238 0.0066 0.990 77 0.256 (0.208 to 0.305)
Five domains 0.1019 0.9283 − 0.25 0.917 5.3426 0.3755 0.915 77 0.0649 (0.016 to 0.114)
Model fit 0 1 0 1  > 0.05  > 0.7 Lower bound 95%CI < 0.05
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the SScQoL were retained following its revision in Ger-
man. Similar to the prior multinational cross-cultural 
validation using Rasch analysis [13], the SScQoL demon-
strated adequate fit when the items were grouped into the 
five domains. Validity, reliability and unidimensionality of 
the German SScQoL was demonstrated. Additionally, the 
tool had good targeting for patients with different levels 
of HRQoL and was shown to be free of response bias for 
age, sex, education level, disease subcategory, and disease 
duration (DIF analysis shown in Additional Files 4 and 5). 
Overall, fit to the Rasch model confirmed that the meas-
urement properties of the revised German SScQoL ver-
sion integrating a 4-point response option were retained.
Having a 4-point response structure means that the 
total score will range from 0 to 87 (i.e. scoring always = 3, 
usually = 2, sometimes = 1, never = 0) which differs from 
the original SScQoL (score range: 0–29). For interoper-
ability in research settings, the polytomous scale could be 
re-scored dichotomously (i.e. ‘always’, ‘usually’ or ‘some-
times’ = ‘true’/1, ‘never’ = ‘not true’/0). We tested this 
scoring approach and it showed adequate fit to the model 
(Additional File 6). Instructions for scoring are included 
in Additional File 7.
The study has several limitations. First, the valida-
tion was only planned when the MANOSS project was 
already established and did not allow for confirma-
tion of the self-reported diagnosis, multiple measure-
ment points and multinational validation [18]. For the 
cognitive interviews, only six Swiss and German patients 
were included. Including more patients (i.e. from Austria 
and Liechtenstein) would have been ideal, although this 
was not possible. Field testing with more patients from 
all German-speaking countries could further improve 
the linguistic presentation of the SScQoL, although we 
believe conceptual equivalence is more important [15]. 
Our validation sample only included Swiss German-
speaking patients. Thus, caution is warranted when 
attempting to extend findings to other German-speak-
ing populations. Further studies should include patients 
from Austria, Germany and Liechtenstein to confirm the 
robustness of the German SScQoL and ensure transfer-
ability. Last, while the instrument is well targeted and 
the sample size adequate for its validation [25], calibra-
tion of the scale into interval-level (transformed) scores 
was beyond the scope of this study. Future work should 
include establishing responsiveness of the SScQoL and 
calibration or cross-cultural comparability studies using 
data from other European countries.
Conclusions
The data presented herein contributes to the existing lit-
erature through the successful revision and validation of 
the SScQoL, with a new 4-point response structure for 
the German speaking context. These data are relevant 
to the broader rare disease research community as they 
demonstrate that cognitive interviews and Rasch analysis 
Fig. 1 Person‑item distribution for all 29 items of the German Systemic Sclerosis Quality of Life Questionnaire (SScQoL)
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can improve the psychometric properties of PROMs 
while enabling interoperability of findings. Further cross-
cultural validity tests are required to fully demonstrate 
measurement equivalence with other SScQoL versions, 
thereby enabling broad, multilinguistic comparison and 
data pooling. Beyond research, the new German SScQoL 
is a  valid measure that can be used with confidence in 
clinical practice. The new version of the SScQoL can be 
obtained at https:// doi. org/ 10. 5518/ 325.
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